Commonwealth Equity Services
NKTR icon

Commonwealth Equity Services’s Nektar Therapeutics NKTR Stock Holding History

Commonwealth Equity Services’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-847
Closed -$8K – 3981
2023
Q3 		$8K Sell
847
-6
-0.7% -$58 ﹤0.01% 3789
2023
Q2 		$7K Sell
853
-307
-26% -$3.27K ﹤0.01% 3801
2023
Q1 		$12 Sell
1,160
-4
-0.3% -$121 ﹤0.01% 3712
2022
Q4 		$39K Sell
1,164
-220
-16% -$10.6K ﹤0.01% 3536
2022
Q3 		$66K Sell
1,384
-3
-0.2% -$178 ﹤0.01% 3442
2022
Q2 		$79K Sell
1,387
-180
-11% -$11.4K ﹤0.01% 3416
2022
Q1 		$126K Sell
1,567
-30
-2% -$4.44K ﹤0.01% 3439
2021
Q4 		$323K Sell
1,597
-415
-21% -$90K ﹤0.01% 2903
2021
Q3 		$541K Buy
2,012
+248
+14% +$59.6K ﹤0.01% 2414
2021
Q2 		$453K Buy
1,764
+16
+0.9% +$4.43K ﹤0.01% 2543
2021
Q1 		$524K Buy
1,748
+65
+4% +$20.2K ﹤0.01% 2297
2020
Q4 		$429K Sell
1,683
-29
-2% -$7.49K ﹤0.01% 2262
2020
Q3 		$425K Sell
1,712
-117
-6% -$36.8K ﹤0.01% 2078
2020
Q2 		$635K Buy
1,829
+56
+3% +$17.5K ﹤0.01% 1721
2020
Q1 		$474K Sell
1,773
-84
-5% -$26K ﹤0.01% 1730
2019
Q4 		$601K Sell
1,857
-202
-10% -$58.6K ﹤0.01% 1761
2019
Q3 		$562K Buy
2,059
+271
+15% +$99.4K ﹤0.01% 1738
2019
Q2 		$954K Buy
1,788
+183
+11% +$91.8K ﹤0.01% 1372
2019
Q1 		$808K Buy
1,605
+393
+32% +$233K ﹤0.01% 1440
2018
Q4 		$597K Buy
1,212
+124
+11% +$74.9K ﹤0.01% 1518
2018
Q3 		$994K Buy
1,088
+191
+21% +$163K ﹤0.01% 1304
2018
Q2 		$657K Buy
897
+297
+50% +$342K ﹤0.01% 1568
2018
Q1 		$956K Buy
600
+237
+65% +$305K 0.01% 1283
2017
Q4 		$325K Buy
+363
New +$215K ﹤0.01% 1995

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Commonwealth Equity Services's NKTR Position: Q4 2023 in Review

Commonwealth Equity Services sold out of Nektar Therapeutics (NKTR) in Q4 2023, closing a stake of 847 shares — an estimated $8K sold.

Commonwealth Equity Services first reported a position in NKTR in Q4 2017 and held it in 24 quarters. The position peaked at $994K in Q3 2018. 125 funds tracked by Wall St. Rank hold NKTR as of Q4 2023.

  • Commonwealth Equity Services reported no remaining Nektar Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Commonwealth Equity Services sold 847 Nektar Therapeutics shares in Q4 2023, an estimated $8K.
  • Commonwealth Equity Services first reported a position in Nektar Therapeutics in Q4 2017 and held it in 24 quarters.
  • Commonwealth Equity Services's Nektar Therapeutics position peaked at $994K in Q3 2018.
  • 125 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2023.

Based on Commonwealth Equity Services's 13F filing for Q4 2023, filed 6 Feb 2024.